Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ence of transmission of HBV, HCV, or HIV, and no clinically relevant anti-C1 inhibitor antibodies developed

In a poster entitled, 'Open-Label Use of Nanofiltered C1 Esterase Inhibitor (human) (nf-C1 INH) for the Prophylaxis of Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects,' Dr. Colin Broom M.D., ViroPharma Incorporated, Exton, PA, presented new open label results of Cinryze in preventing HAE attacks in 23 pediatric patients with HAE.  Data from this study included the following:

  • Cinryze reduced the frequency of HAE attacks from a median of 3.0 attacks per month at baseline to 0.39 attacks per month during Cinryze prophylaxis
  • In children, prophylactic doses of 1000 U of Cinryze every 3 to 7 days resulted in increases in antigenic and functional C1-INH levels comparable to those seen in adults; increases in functional C1-INH activity were maintained over time
  • There were no severe hypersensitivity reactions related to Cinryze; no discontinuations from study due to adverse events; no detectable anti-C1 INH antibodies; and no evidence of transmission of HBV, HCV, or HIV;
  • Adverse events considered to be possibly, probably, or definitely related to Cinryze were headache, nausea, and infusion site erythema, none of which were considered severe.

In addition, the WAO has joined with The American College of Allergy, Asthma and Immunology (ACAAI) and the American Gastroenterological Association (AGA) Institute in an innovative  initiative called "HAE:  Learn About It, Talk About It."  The peer-driven campaign is designed to foster communication between physicians on the front lines of the diagnosis and management of HAE. The addition of WAO as a "Learn About It, Talk About It" partner expands the program to a global audience. The program will be highlighted in booth 13 at the WAO meeting.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  Casen Buswell has a rare ... to harden.  His case is one of only 14 known ... The only hospital in the United States ... offering treatment with the dual wave-length laser, is Methodist Children,s ... Antonio . Using a laser available in ...
(Date:9/18/2014)... Sept. 18, 2014 This BCC Research report discusses the ... players, market growth and size, and opportunities for different devices ... through 2018. Patent analysis in the report focuses on technological ... Europe and Japan ... and discuss the global medical device technologies market. - Analyze ...
(Date:9/18/2014)... and LONDON , ... era for biopharmaceutical companies. Competition for innovation, increasing ... to keep up with the fast-changing environment are ... influence clinical trials, and clinical trial costs continue ... patient recruitment. Studies conducted by industry ...
Breaking Medicine Technology:Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Medical Devices: Technologies and Global Markets 2Medical Devices: Technologies and Global Markets 3Medical Devices: Technologies and Global Markets 4Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... March 2007 - Cancer drug,developer Antisoma plc (LSE: ... from its second, confirmatory phase II,trial of AS1404 ... trial tested an 1800 mg/m2 dose of AS1404 ... response rate of 50%. A further 43% of,patients ...
... BioSciences,Inc., a specialty dermatology company, today announced the,publication of ... the journal,Cell by its co-founder and board member, David ... an important protein,p53, in the pigmentation of skin. Fisher's ... tumor suppressor in other cancers in,the body, p53 also ...
Cached Medicine Technology:Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 2Antisoma plc (UK) - Second lung cancer trial adds to positive data,on AS1404 3Study in Cell by Magen BioSciences Co-Founder David E. Fisher,Identifies New Roles in Skin Cancer Prevention for Key Tumor,Suppressor Protein 2
(Date:9/18/2014)... September 18, 2014 Alexandria, VA — ... today that 10 more communities have joined the growing ... health department accreditation. The decisions bring the number of ... 54. PHAB is the non-profit organization that administers the ... and protect the health of the public by advancing ...
(Date:9/18/2014)... 18, 2014 (HealthDay News) -- Rising temperatures in the ... spread to shallow waters that are becoming warmer, an ... reefs, ecologists report. A study of 40 species ... northward movement by the invasive and poisonous lionfish, according ... (NOAA) and the University of North Carolina-Wilmington, who published ...
(Date:9/18/2014)... "Medical staff need better ways to ... the patient's privacy," said one of two inventors from ... order to supply caregivers with the equipment they need ... prototype for The Helper to make it easier to ... patient onto his or her side. It also securely ...
(Date:9/18/2014)... One of the most capable and sophisticated ... ShandsCair Flight Program’s new EC155 B1, will be ... the Air Medical Transport Conference (AMTC), Sept. 22-24, in ... service ShandsCair EC155 and the Vanderbilt University LifeFlight ... highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... patients seeking care at larger urban hospitals are likely to ... at smaller or more rural facilities, new research suggests. ... emergency care varies dramatically across hospitals in the United States," ... Renee Hsia, an associate professor at the University of California, ...
Breaking Medicine News(10 mins):Health News:Ten More Communities Reaping Benefits of National Accreditation 2Health News:Ten More Communities Reaping Benefits of National Accreditation 3Health News:Ten More Communities Reaping Benefits of National Accreditation 4Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3
... ... a clinical trial that is testing whether specialized contact lenses can slow or halt ... and Robert Davis, working with EyeVis Eye and Vision Research Institute, recently reported on ... , ...
... Family Research Council President Tony Perkins responded to ... Obama,s executive order for federal funding of human embryonic ... the NIH guidelines remove life-protecting limits on federal funding ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) ...
... ... a national leader in accounts receivable management, and collection services to the healthcare industry has ... in Vero Beach, Florida. , ... Vero Beach, FL (PRWEB) July 7, 2009 -- National healthcare receivables industry leader, Medical ...
... a Woman,s Right to Choose , , ARLINGTON ... breast reconstruction procedures performed in 2008, nearly 70 percent ... not informed of the reconstructive options available to them, ... by the American Society of Plastic Surgeons (ASPS) shows ...
... July 7 The Anthropedia Foundation, a non-profit organization ... Know Yourself , an innovative DVD series designed ... and healthier lives. The series is a step-by-step guide ... part focuses on straightforward concepts and simple exercises that ...
... sellers appears to reduce the trafficking of guns to ... the Johns Hopkins Bloomberg School of Public Health. Preventing ... 85 percent of guns recovered by police were recovered ... of the guns according to prior research from the ...
Cached Medicine News:Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 2Health News:Can a Contact Lens Cure Nearsightedness? Five-Year Clinical Study Testing Corneal Reshaping Therapy as Possible Method to Arrest Myopia 3Health News:NIH Stem Cell Guidelines Ethically Irresponsible, Scientifically Unworthy, Useless to Patients, Says Family Research Council 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 2Health News:Medical Data Systems, Inc. (MDS) Announces Operations Expansion and Opening of its Primary Collections Operations Office 3Health News:Are Breast Cancer Patients Being Kept In The Dark? 2Health News:Knowing Yourself Can Improve Your Health and Happiness 2Health News:Knowing Yourself Can Improve Your Health and Happiness 3Health News:Regulation and oversight of gun sales reduces trafficking to criminals 2Health News:Regulation and oversight of gun sales reduces trafficking to criminals 3
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: